QMS in a Box：開発フェーズに応じた品質管理スターターキット

QMS in a Box: A Phase-Appropriate Quality Management Starter Kit

9/12/2025

by Tracy TreDenick
BioTechLogic Co-Founder & Head of Regulatory and Quality

Download this paper in PDF
‍

‍

Early-stage biopharma companies often face the same challenge: the need for quality oversight arises long before they are prepared to hire a full-time in-house QA team and/or at a time when they lack the resources to build a Quality Management System (QMS). QMS in a Box is a right-sized, phase-appropriate solution designed for companies that outsource manufacturing and testing. It provides an individualized starter set of Standard Operating Procedures (SOPs), vendor enrollment checklist, executable forms and templates and, when needed, experienced QA resources to implement them.

Developed by experts who have worked in Quality for decades, these SOPs help companies establish the foundation for FDA Phase 1 compliance, vendor qualification, and support the release of phase 1 and 2 clinical supplies. QMS in a Box allows teams to move quickly from preclinical proof-of-concept to GLP toxicology studies and ultimately to their first clinical batch—without losing time or credibility with regulators, investors, or partners.

In this paper, we will take a look at the following:

I. Virtual biopharma company tendencies and associated risks

II. Signs that it’s time to consider QMS in a Box

III. What does phase-appropriate mean?

IV. Included in QMS in a Box

V. How QMS in a Box works in practice

VI. Required steps for implementation of a QMS

VII. Supported modalities/product types

VIII. Benefits to early-stage companies

IX. Limitations/geographic scope

X. Conclusion

‍

I. Virtual biopharma company tendencies and associated risks

QMS in a Box was explicitly designed for virtual sponsor biopharma companies: organizations relying on CDMOs and external labs rather than building in-house manufacturing capabilities. Virtual biopharma companies typically prioritize R&D in the early years, delaying QA infrastructure until the initial public offering (IPO). Doing so without QA consulting services acting as your QA infrastructure courts a high degree of risk, especially in these three areas:

• Vendor Qualification: CROs, CDMOs, and testing labs must be audited and approved before clinical trial materials are release and studies commenced.
• Data and Documentation Integrity: Investors and regulators expect systems that ensure traceability, data integrity and established procedures that are followed.
• Batch Release: By the time a clinical batch is ready, QA oversight and supporting SOPs must be firmly in place.

Without a scalable approach, writing SOPs from scratch can take 12–18 months, jeopardizing timelines and investor confidence. QMS in a Box solves this problem with a pre-built, phase-appropriate quality system tailored to the needs of virtual biopharma.

Key advantages include:

• Electronic Document Management (EDMS) Integration that is compatible with systems like Veeva, MasterControl, or ZenQMS.
• 21 CFR Part 11 Compliance to ensure that electronic signatures, a necessity for virtual companies with regionally based employees, are compliant and can therefore be accepted by FDA as legally binding.‍
  ‍

II. Signs that it’s time to consider QMS in a Box

Three triggers in particular may signal that it is time to implement this type of support:  

1. Vendor Qualification: at the time when a CRO/CDMO is first identified and engaged. Vendor qualification is needed to ensure proper oversight of the vendor’s compliance and that the necessary quality agreements are in place.
2. GLP Toxicology Studies: at the moment when QA oversight becomes mandatory due to preclinical studies. Tox specification must be approved to ensure control of tox material and acceptance of test article by CRO and for the safety of animals for dose administration; QMS in a Box has the SOP to address this.
3. Pre-Clinical to Clinical Transition: with at least 9 months of lead time before the first clinical batch release (e.g. before a product is used on a human).

By starting early, companies avoid last-minute crises and ensure that SOPs, training, and QA sign-off are in place when critical milestones arrive.

‍

III. What does phase-appropriate mean?

A phase-appropriate quality system describes an approach in which sponsor companies implement procedures and processes that are based on FDA’s Phase 1 GMP guidance but that also takes into consideration regulatory requirements from ICH E6 and 21 CFR 58. This ensures that the appropriate level of oversight is given to CROs, CDMOs and testing lab, and is appropriate for the particular phase of development, such as Phase 1 Clinical Trials.

‍

IV. Included in QMS in a Box

At its core, QMS in a Box is a starter set of SOPs covering essential quality functions across GxP domains. These include:

• Document Management
• “SOP on SOPs” (governance for procedure creation and use)
• Training Program
• Vendor qualification
• Issues and CAPAs
• Change control
• Specifications Generation, and more

These SOPs are:

• Phase-appropriate: focused on early development needs rather than being overbuilt for commercialization
• Right-sized: lean enough for resource-constrained startups, but robust enough for sponsor and investor scrutiny
• Proven: reviewed and validated by the industry’s foremost Quality consulting experts

In addition, companies can engage QA resources to execute and manage these systems. BTL and DHC employee numerous experts with the necessary knowledge to act as either:

• Head of QA: providing strategic oversight and/or
• QA Manager: handling day-to-day SOP implementation and approvals at a lower cost

‍

‍V. How QMS in a Box works in practice

Implementation typically follows a phased approach:

1. Foundation (Tranche 1) – Establish baseline SOPs and document management.
2. GLP Readiness (Tranche 2) – Add SOPs required for vendor qualification and toxicology studies.
3. Clinical Batch Release (Tranche 3) – Expand SOPs to cover batch release, inventory, and stability requirements.

This “tranche” model ensures that each client has the option to build out their Quality systems in lock-step with development, avoiding both under-preparation and over-engineering.

‍

‍

‍VI. Required steps for implementation of a QMS

In order:

1. Implement a phase-appropriate Quality Management System per FDA Phase 1 GMP, GLPs for Sponsor’s oversight/monitoring of studies and GCP requirements (clinical ops/clinical development)
2. Draft and manage approval of phase-appropriate GxP SOPs
3. Implement and maintain integrated EDMS-LMS (Part 11-Compliant electronic signature and approval) or implement and manage electronic signature Part 11-Compliant DocuSign
4. Perform batch release
5. Manage GMP inventory: quarantine, authorization to ship, etc. (paper-based and electronic)

‍

VII.     Supported modalities/product types

QMS in a Box can support any modality or product type that DHC or BTL supports. A non-exhaustive list of the most common product types is as follows:

• Primary cells and tissues
• iPSCs, ESCs (incl. gene-modified)
• HSCs, MSCs (incl. gene-modified)
• T cells (aβ, γδ, Treg), TILs, NK cells, B cells, DCs (incl. gene-modified)
• Viral gene delivery (LVV, AdV, AAVs, RVs)
• Non-viral gene delivery (mRNA, exosomes, LNPs, etc.)
• Gene editing (CRISPR/Cas, ZFN, TALEN, base editors, etc.)
• Recombinant proteins including fusion proteins
• Biosimilars
• Complex antibodies
• 合成高分子（オリゴヌクレオチドおよびペプチドを含む）
• ワクチンおよびアジュバント
• 血液製剤
• コンビネーション製品

‍

VIII.   アーリーステージ企業へのメリット

アーリーステージ企業へのメリット

• スピード – 社内で作成に12〜18ヶ月かけることなく、SOPを即座に利用可能です。
• コスト効率 – 柔軟なQAリソースの活用により、オーバーヘッドを削減します。
• 投資家の信頼 – 準備状況、コンプライアンス、データ整合性を証明します。
• 拡張性 – GLP試験から治験薬のリリースまで、プログラムの成長に合わせて対応可能です。

‍

IX.   制限事項／地理的範囲

QMS in a Boxは、米国FDAの第1相GMPガイダンス文書への準拠を確実にするよう設計されています。このガイダンスは米国特有のものであるため、QMS in a Boxも米国市場に特化しています。

したがって、これらのSOPは、直接的な初期段階のガイダンスが存在せず、指令に従う必要がある欧州（EMA/MHRA）の規制環境をサポートするようには設計されていません。QMS in a Boxはグローバルな使用に合わせて調整可能ですが、この既製品パッケージは米国専用です。

BioTechLogicとDark Horse Consultingは、その他のすべてのグローバル市場においても高度な品質サポートを提供しています。違いは、米国以外ではこのレベルのサポートに追加のカスタマイズが必要となる点のみです。

現在、米国においてフェーズに応じたGMPを規定する規制は以下の通りです。

米国法

• 連邦食品・医薬品・化粧品法（FD&C Act）第501条(a)(2)(B)（21 U.S.C. 351 (a)(2)(B)）は、IND製品を含む医薬品に対し、現行の医薬品適正製造基準（cGMP）への準拠を義務付けています。
• 21 CFR Part 11 電子署名

米国ガイダンス文書

• 21 CFR 58 (GLP) – スポンサーによる監督
  ‍
• ICH E6 (GCP)
  記録の保持、配布記録
  治験薬はGMPに従って製造、取り扱い、保管されるべきである

• FDA 第1相GMP（医薬品）
  トレーニング、変更管理、文書管理、有資格者、品質部門によるSOP・試験手順・判定基準の審査と承認など

‍

‍

X. 結論

すべてのバイオ医薬品スタートアップ（スポンサー企業など）は、「品質管理は後回しでいい」という誘惑に直面します。しかし、「後で」は往々にして「手遅れ」を意味します。「QMS in a Box」は、フェーズに応じたSOPとQAサポートを必要なタイミングで提供することでそのギャップを埋め、規制当局の期待、ベンダー監査、臨床用バッチのリリースに向けた万全の準備を支援します。

社内にQAリソースがある場合でも、外部サポートが必要な場合でも、「QMS in a Box」は、コンプライアンスを遵守し、投資家への対応が可能な品質フレームワークを構築するための近道となります。

‍